AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
ASTRAZENECA PLC
Financials through Q2 FY2026, quarter ended Jun 30, 2026
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026
- Market cap
- $255.76B
- P/E (TTM)
- 25.1
- Dividend yield
- 1.91%
ASTRAZENECA PLC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 21 | TTM Q1 21 | TTM Q4 20 | TTM Q3 20 | TTM Q2 20 | TTM Q1 20 | TTM Q4 19 | TTM Q3 19 | TTM Q2 19 | TTM Q1 19 | TTM Q4 18 | TTM Q3 18 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Oncology | $12.01B | $11.33B | $10.85B | $10.22B | $9.72B | $9.28B | $8.67B | $8.16B | $7.42B | $6.69B | $6.03B | $5.38B | 41.4% | +23.5% |
| BioPharmaceuticals: total CVRM | $7.57B | $7.31B | $7.10B | $7.04B | $6.99B | $6.89B | $6.91B | $6.87B | $6.81B | $6.78B | $6.71B | $6.90B | 26.1% | +8.2% |
| BioPharmaceuticals: total Respiratory & Immunology | $5.65B | $5.35B | $5.36B | $5.37B | $5.52B | $5.66B | $5.39B | $5.22B | $5.04B | $5.01B | $4.91B | $4.88B | 19.5% | +2.3% |
| Tagrisso | $4.77B | $4.50B | $4.33B | $4.06B | $3.79B | $3.54B | $3.19B | $2.90B | $2.51B | $2.15B | $1.86B | $1.57B | 16.4% | +25.7% |
| Symbicort | $2.65B | $2.62B | $2.72B | $2.75B | $2.77B | $2.70B | $2.50B | $2.42B | $2.43B | $2.51B | $2.56B | $2.68B | 9.1% | -4.3% |
| Total Other medicines | $2.47B | $2.58B | $2.59B | $2.51B | $2.50B | $2.58B | $2.60B | $2.84B | $2.94B | $3.05B | $3.40B | $3.60B | 8.5% | -1.4% |
| Farxiga | $2.47B | $2.18B | $1.96B | $1.79B | $1.67B | $1.60B | $1.54B | $1.52B | $1.48B | $1.44B | $1.39B | $1.33B | 8.5% | +48.2% |
| Imfinzi | $2.25B | $2.14B | $2.04B | $1.91B | $1.79B | $1.64B | $1.47B | $1.31B | $1.08B | $866.00M | $633.00M | $389.00M | 7.7% | +25.6% |
| Lynparza | $2.09B | $1.92B | $1.78B | $1.63B | $1.49B | $1.36B | $1.20B | $1.06B | $898.00M | $765.00M | $647.00M | $538.00M | 7.2% | +40.0% |
| Nexium | $1.52B | $1.56B | $1.49B | $1.47B | $1.44B | $1.46B | $1.48B | $1.52B | $1.57B | $1.62B | $1.70B | $1.74B | 5.2% | +5.2% |
| Brilinta | $1.50B | $1.56B | $1.59B | $1.66B | $1.69B | $1.64B | $1.58B | $1.53B | $1.45B | $1.38B | $1.32B | $1.24B | 5.2% | -11.4% |
| Crestor | $1.14B | $1.15B | $1.18B | $1.18B | $1.22B | $1.24B | $1.28B | $1.34B | $1.35B | $1.38B | $1.43B | $1.67B | 3.9% | -6.4% |
| Fasenra | $1.10B | $1.01B | $949.00M | $872.00M | $834.00M | $774.00M | $704.00M | $623.00M | $507.00M | $405.00M | $297.00M | – | 3.8% | +32.3% |
| Pulmicort | $1.02B | $946.00M | $996.00M | $1.04B | $1.23B | $1.46B | $1.47B | $1.44B | $1.37B | $1.32B | $1.29B | $1.27B | 3.5% | -17.2% |
| Seloken/Toprol-XL | $941.00M | $893.00M | $821.00M | $810.00M | $762.00M | $712.00M | $760.00M | $730.00M | $732.00M | $737.00M | $712.00M | $720.00M | 3.2% | +23.5% |
| Zoladex | $911.00M | $884.00M | $888.00M | $868.00M | $864.00M | $844.00M | $813.00M | $799.00M | $767.00M | $762.00M | $752.00M | $757.00M | 3.1% | +5.4% |
| Calquence | $816.00M | $643.00M | $522.00M | $396.00M | $295.00M | $223.00M | $164.00M | $132.00M | $106.00M | $83.00M | $62.00M | $41.00M | 2.8% | +176.6% |
| Other R&I | $505.00M | $445.00M | $398.00M | $408.00M | $420.00M | $451.00M | $467.00M | $438.00M | $406.00M | $393.00M | $545.00M | $318.00M | 1.7% | +20.2% |
| Faslodex | $495.00M | $536.00M | $580.00M | $616.00M | $683.00M | $804.00M | $892.00M | $995.00M | $1.05B | $1.03B | $1.03B | $997.00M | 1.7% | -27.5% |
| Bydureon | $429.00M | $450.00M | $448.00M | $464.00M | $482.00M | $507.00M | $549.00M | $548.00M | $573.00M | $587.00M | $584.00M | $593.00M | 1.5% | -11.0% |
| Onglyza | $415.00M | $431.00M | $470.00M | $497.00M | $514.00M | $515.00M | $527.00M | $544.00M | $557.00M | $567.00M | $543.00M | $575.00M | 1.4% | -19.3% |
| FluMist | $298.00M | – | $295.00M | – | – | – | – | – | – | – | – | – | 1.0% | – |
| Synagis | $244.00M | $310.00M | $372.00M | $356.00M | $384.00M | $390.00M | $358.00M | $546.00M | $564.00M | $494.00M | $665.00M | $648.00M | 0.8% | -36.5% |
| Iressa | $229.00M | $252.00M | $268.00M | $281.00M | $318.00M | $366.00M | $423.00M | $455.00M | $495.00M | $520.00M | $518.00M | $536.00M | 0.8% | -28.0% |
| Daliresp/Daxas | $225.00M | $224.00M | $217.00M | $221.00M | $217.00M | $220.00M | $215.00M | $211.00M | $210.00M | $199.00M | $189.00M | $188.00M | 0.8% | +3.7% |
| Losec/Prilosec | $184.00M | $183.00M | $183.00M | $190.00M | $218.00M | $241.00M | $263.00M | $277.00M | $271.00M | $279.00M | $272.00M | $281.00M | 0.6% | -15.6% |
| Other CVRM | $183.00M | $184.00M | $192.00M | $218.00M | $244.00M | $259.00M | $271.00M | $274.00M | $282.00M | $292.00M | $306.00M | $311.00M | 0.6% | -25.0% |
| Atacand | $174.00M | $210.00M | $243.00M | $239.00M | $240.00M | $237.00M | $221.00M | $219.00M | $229.00M | $239.00M | $260.00M | $275.00M | 0.6% | -27.5% |
| Casodex | $166.00M | $172.00M | $172.00M | $176.00M | $184.00M | $194.00M | $200.00M | $203.00M | $202.00M | $197.00M | $201.00M | $209.00M | 0.6% | -9.8% |
| Arimidex | $151.00M | $180.00M | $185.00M | $201.00M | $222.00M | $224.00M | $225.00M | $220.00M | $212.00M | $209.00M | $212.00M | $223.00M | 0.5% | -32.0% |
| Other, Others | $122.00M | $120.00M | $126.00M | $238.00M | $275.00M | $303.00M | $193.00M | $190.00M | $169.00M | $165.00M | $290.00M | $266.00M | 0.4% | -55.6% |
| Lokelma | $121.00M | $99.00M | $76.00M | $57.00M | $40.00M | $25.00M | $14.00M | – | – | – | – | – | 0.4% | +202.5% |
| Seroquel XR/IR | $104.00M | $110.00M | $117.00M | $138.00M | $185.00M | $190.00M | $191.00M | $207.00M | $202.00M | $301.00M | $361.00M | $461.00M | 0.4% | -43.8% |
| Breztri | $99.00M | $50.00M | $28.00M | $22.00M | $13.00M | – | $2.00M | – | – | – | – | – | 0.3% | +661.5% |
| Koselugo | $77.00M | $58.00M | $38.00M | – | – | – | – | – | – | – | – | – | 0.3% | – |
| Byetta | $66.00M | $65.00M | $68.00M | $77.00M | $90.00M | $100.00M | $110.00M | $115.00M | $121.00M | $125.00M | $126.00M | $142.00M | 0.2% | -26.7% |
| Bevespi | $52.00M | $49.00M | $48.00M | $48.00M | $44.00M | $44.00M | $42.00M | $40.00M | $40.00M | $38.00M | $33.00M | $31.00M | 0.2% | +18.2% |
| Other Oncology | $51.00M | $50.00M | $51.00M | $64.00M | $71.00M | $87.00M | $94.00M | $91.00M | $99.00M | $108.00M | $115.00M | $121.00M | 0.2% | -28.2% |
| Other diabetes | $51.00M | $46.00M | $47.00M | $50.00M | $53.00M | $54.00M | $52.00M | – | – | – | – | – | 0.2% | -3.8% |
| Duaklir | – | – | – | – | – | – | – | – | $82.00M | $87.00M | $95.00M | $96.00M | – | – |
| Movantik/Moventig | – | – | – | – | – | – | – | – | $104.00M | $106.00M | $109.00M | $114.00M | – | – |
| Symlin | – | – | – | – | – | – | – | – | $33.00M | $32.00M | $34.00M | $37.00M | – | – |
| Eklira/Tudorza | – | – | – | – | – | – | – | – | $70.00M | $96.00M | $110.00M | $133.00M | – | – |
| FluMist/Fluenz | – | – | – | – | – | – | – | – | – | – | $110.00M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Astrazeneca's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.